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A B S T R A C T
Viruses are by far the most abundant parasites on earth and they have been found to infect animals,
plants and bacteria. However, different types of viruses can only infect a limited range of hosts andmany
are species-speciﬁc. Herpesviruses constitute a large family of DNA viruses that cause diseases in
animals, including humans and that are known to undergo lytic or latent infections. Consequently, they
developed numerous strategies to counteract host antiviral responses to escape immune surveillance.
Innate immune response constitutes the ﬁrst line of host defence that limits the viral spread and also
plays an important role in the activation of adaptive immune response. Viral components are recognized
by speciﬁc host Pathogen Recognition Receptors (PRRs) which trigger the activation of IRF3, NF-kB and
AP-1, three regulators of IFN-b expression. IFN-b is responsible for the induction of Interferon-
Stimulated Genes (ISGs) that encode antiviral effectors important to limit the viral spread and to
establish an antiviral state as well in the infected cells as in the neighbouring non-infected cells. In this
review, we will summarize how host cells recognize viral components and activate downstream
signalling pathways leading to the production of IFN-b and ISGs. We will also review the most recent
ﬁndings in Herpesviruses-encoded proteins involved in host immune evasion.
 2010 Elsevier Inc. All rights reserved.
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The immune response directed to pathogens like viruses
proceeds in two steps. Innate immune response, that represents
the ﬁrst line of defence, is rapidly activated and plays an important
role in the detection of invading pathogens and in the limitation of
their spread. The adaptive immunity, that represents the second
line of defence, takes more time to be settled and is involved in the
total clearance of pathogens.
Innate immune cells express various Pattern-Recognition
Receptors (PRRs) that recognize conserved microbial molecules
known as Pathogen-Associated Molecular Patterns (PAMPs) such
as viral nucleic acids and bacterial components such as LPS or
ﬂagellin.
To date, three classes of PRRs have been discovered, namely (i)
Toll-Like Receptors (TLRs) that are membrane-associated recep-
tors, (ii) Retinoic acid-Inducible Gene (RIG-I)-Like Receptors (RLRs)
and (iii) Nucleotide-binding Oligomerization Domain (NOD)-Like
Receptors (NLRs) that are cytosolic receptors [1–4]. Recently
another sensor, which localizes into the cytosol, has been
identiﬁed. This new receptor has been called DNA-dependent
Activator of IRFs (DAI) and recognizes bothmicrobial and host DNA
[5,6]. AIM2 (Absent in Melanoma 2), has also been identiﬁed as a
DNA sensor that controls the catalytic cleavage of pro-form of the
cytokine IL-1b [7,8].
Viral detection by TLRs, RLRs and DAI leads to the expression of
Type I interferons (IFNs) (IFN-a/-b) and pro-inﬂammatory
cytokines such as IL-8, RANTES and IL-1b whereas NLRs and
AIM2 are involved in caspase-1-mediated maturation of IL-1b
[3,7–10]. These cytokines are important for recruitment and
activation of the immune effector cells (i.e. neutrophiles, B
lymphocytes, T lymphocytes. . .). Because IFN-a and -b induce
the expression of genes encoding antiviral proteins, they are
considered as key players in the innate antiviral response. IFN-a
and -b represent also an important link between innate and
adaptive immune responses [11].
Herpesviruses are largely widespread in the environment and
so far, approximately 130 of them have been identiﬁed. Nine of
them are human pathogens namely, Herpes Simplex Virus type-1
(HSV-1), Herpes Simplex Virus type-2 (HSV-2), Human Cytomeg-
alovirus (HCMV), Varicella-Zoster Virus (VZV), Epstein-Barr Virus
(EBV) and Human Herpesvirus type-6A, 6B, 7, and 8 (HHV-6A,
HHV-6B, HHV-7, and HHV-8). According to the primary target cell
and the site of latency, they have been classiﬁed in three
subfamilies, (i) the Alphaherpesvirinae, (ii) the Betaherpesvirinae
and (iii) the Gammaherpesvirinae.
Structurally, Herpesviruses are enveloped viruses with a long
dsDNA genome. The replication cycle occurs in three waves. The
ﬁrst wave leads to the expression of the immediate-early genes (IE
or a) that occurs independently of de novo viral protein synthesis.
They encode key regulators that will allow the expression of the
second wave of genes: the early genes (E or b). E proteins areinvolved in the viral DNA replication. During the third wave, the
late genes (L or g) are expressed. Those encode structural proteins
such as capsid and tegument proteins, as well as glycoproteins. All
Herpesviruses share a common feature which is the ability to
establish a lifelong infection by undergoing latency in their host
after primary infection. During this latency, the viral DNA is
present in the infected cells but no replication is observed even if
some viral proteins are expressed. Upon stimuli that are not clearly
deﬁned, the virus can reactivate and reinitiate a lytic infectious
cycle. Therefore, Herpesviruses have developed mechanisms to
bypass the immune responses of their host to persist in it.
In this review, we will describe how viral components are
recognized by host PRRs and how Human Herpesviruses (i.e. HSV-
1, VZV, HCMV and EBV) subvert their host’s innate immune
responses.
2. The Toll-like receptor family
The role of the TLRs in innate immunity was ﬁrst described in
Drosophila melanogaster [12]. The Toll receptor has been shown to
possess homologs in humans referred to as Toll-Like Receptors. To
date, 11 TLRs members have been described in humans [13–15].
Theywere shown to bind conservedmicrobial molecules known as
PAMPs that are shared by many pathogens but not expressed by
the host. This enables them to discriminate the ‘‘non-self’’ from the
‘‘self’’. TLRs recognize various microbial components such as
bacterial lipopolysaccharide (LPS), ﬂagellin, peptidoglycan, CpG-
rich DNA but also yeast wall mannans and viral nucleic acids. The
cellular localization, the ligand and the adaptor proteins of each
TLR are summarized in Table 1.
TLRs are type I transmembrane proteins that share common
structural features (Fig. 1). They are composed by a variable N-
terminal extracellular ectodomain containing 16–28 leucine-rich
repeats (LRRs) that are responsible for the detection and the
interaction with PAMPs [16]. Contrary to the LRR, the C-terminal
intracellular domain of the TLRs is highly conserved and similar to
the intracellular region of the Drosophila Toll and IL-1 receptors
[16]. This intracellular domain, known as Toll/IL-1 Receptor (TIR)
domain, allows the transduction signal to the nucleus [4,13]. TLRs
are expressed in innate immune cells that encounter pathogens,
such as monocytes and macrophages, but also in B-lymphocytes
and dendritic cells [14]. However, expression of TLRs in dendritic
cells varies according to the subset of these later. Indeed, human
blood dendritic cells contain two subsets: myeloid dendritic cells
(mDCs) and plasmacytoid dendritic cells (pDCs). Mature mDCs
express TLRs-2, -3, -4, -5, -6, -7 and -8, whereas mature pDCs only
express TLRs-7 and -9 [17]. Nevertheless, TLRs expression is not
restricted to these cells as they are also expressed in various cell
and tissue types such as vascular endothelial cells, adipocytes,
cardiac myocytes and intestinal epithelial cells [18]. TLRs are
mainly expressed on the cell surface except the TLRs-3, -7, -8 and -
9 that are expressed in endosomal compartments [14,19,20].
Table 1
Description of the Toll-like receptors family (adapted from [4,14]).
TLR Localization Ligand Adaptor
TLR1/2 Cell surface Triacyl lipopeptides (Bacteria and Mycobacteria) MyD88, TIRAP
TLR2/6 Cell surface Diacyl lipopeptides (Mycoplasma), LTA (Streptococcus), Zymosan (Saccharomyces cerevisiae) MyD88, TIRAP
TLR2 Cell surface Peptidoglycan (Gram-positive bacteria), lipoarabinomannan (Mycobacteria), Hemagglutinin (Measles virus),
phospholipomannan (Candida), Glycosylphosphophatidyl inositol mucin (Trypanosoma)
MyD88, TIRAP
TLR3 Endosome ssRNA virus (West Nile Virus), dsRNA virus, Respiratory Syncitial virus (RSV), murine cytomegalovirus (MCMV) TRIF
TLR4 Cell surface LPS (Gram-negative Bacteria), Mannan (Candida), glycoinositolphospholipids
(Trypanosoma), enveloppe proteins (RSV and MMTV)
MyD88, TIRAP,
TRAM and TRIF
TLR5 Cell surface Flagellin (Flagellated bacteria) MyD88
TLR7 Endosome ssRNA viruses (VSV, Inﬂuenza virus) MyD88
TLR8 Endosome ssRNA from RNA virus MyD88
TLR9 Endosome dsDNA viruses (HSV, MCMV), CpG motifs from bacteria and viruses, hemozoin (Plasmodium) MyD88
TLR11 Cell surface Uropathogenic bacteria, proﬁllin-like molecule (Toxoplasma gndii) MyD88
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nucleic acids that require internalization into endosomes to induce
signalling [20].
2.1. TLR signalling pathways
The PAMPs recognition by TLRs induces the recruitment of
adaptor proteins containing a TIR domain including MyD88, TIRAP
(also known asMAL), TRIF (also known as TICAM1) and TRAM (also
known as TICAM2). Upon stimulation, TLRs recruit adaptors to
transduce the signal and activate transcription factors such as NF-
kB, AP-1 and IRF3 that allow the expression of pro-inﬂammatory
cytokines and IFNs [15,20,21]. Depending on the adaptor protein
that is recruited, TLRs are able to activate different transcription
factors to induce appropriate responses to pathogens. According to
the adaptor and to the TLR, two main pathways can be activated,
namely (i) MyD88-dependent and (ii) TRIF-dependent pathway
(Fig. 2).
2.1.1. MyD88-dependent signalling
Upon ligand recognition, TLRs-1, -2, -4, -5, -6, -7 and -9 recruit
the adaptor protein MyD88 via their respective TIR domain. This
[(Fig._1)TD$FIG]
Fig. 1. Schematic representation of the protein structure of the Toll-Like Receptors.
The ectodomain consists in 16–28 leucine-rich repeats that are variable among
human TLRs and among different species, indicated as grey circle, and involved in
the recognition of PAMPs. A cystein-rich domain (depicted as two white circles) is
present in Drosophila Toll but missing in human TLRs. The ectodomain of the IL-1R
consists in three immunoglobulin-like domains. All TLRs share an intracellular
domain that is indicated as a dark grey ellipse. This TIR domain is involved in the
signal transduction and is highly conserved among human TLRs and among
different species.leads in ﬁne to the activation of NF-kB and AP-1 [22] (Fig. 2, purple
and cyan frames). Once recruited, MyD88 binds the death domain
(DD) of the IL-1 Receptor-Associated Kinase 4 (IRAK4) through
homotypic interactions, resulting in the activation of the
downstream IRAKs such as IRAK1 and IRAK2. Once phosphorylat-
ed, IRAKs are released fromMyD88 and associate with and activate
TNF receptor-associated factor 6 (TRAF6). The binding to TRAF6 is
important for its K63-linked polyubiquitination that, in turn,
allows the recruitment of a larger complex comprising TAB2/TAB3/
TAK1. This induces the phosphorylation of TAK1 which is involved
in the activation of the IkB kinase (IKK) complex leading to the
phosphorylation, polyubiquitination and degradation of IkBa,
which permits the nuclear translocation of NF-kB [4,15,21,23,24]
(Fig. 2).
Keating et al. reported that IRAK2, rather than IRAK1, is
important for TRAF6 K63-linked polyubiquitination and subse-
quent activation of NF-kB upon TLR stimulation [25]. Furthermore,
the complex formed by MyD88/IRAK4/IRAK2 has been recently
crystallized showing how important IRAK2 is in TLR-mediated
activation of NF-kB [26]. The MyD88-dependent pathway also
leads to the activation of Mitogen Activated Protein (MAP) kinases
(MAPKs) such as the Extracellular signal-Regulated Kinase (ERK or
p44/p42), the JUN N-terminal Kinase (JNK) and p38 (Fig. 2, purple
and cyan frames). These MAPKs promote the activation of the
Activator Protein (AP)-1 that plays a role in the control of pro-
inﬂammatory genes expression. Furthermore, in addition to
MyD88, the TLRs-1, -2, -4 and -6 recruit another TIR-containing
adaptor, the TIR-associated protein (TIRAP), which is also known as
MyD88-adaptor-like (MAL) and that serves as a linker adaptor to
recruit MyD88 to the TLRs [4,26,27] (Fig. 2).
In plasmacytoid dendritic cells (pDCs), TLR7- and TLR9-
dependent signalling pathways require MyD88 to induce IFN-a
expression (Fig. 2, grey frame). Upon stimulation with agonist,
TLR7 and TLR9 recruit MyD88 that associates with Interferon-
Regulatory factor (IRF-) 7 along with IRAK4, TRAF6, TRAF3, IRAK1
and IKKa. In this large complex, IRF7 is phospohrylated by IRAK1
and IKKa allowing its nuclear translocation and subsequent
expression of IFN-a (Fig. 2, grey frame). The activation of IRF7 in
pDCs also requires the precursor of osteopontin (OPNi) [4,20]. In
addition to IRF7, TLR7 and TLR9 trigger the activation of NF-kB
through a MyD88/IRAK4/IRAK2/TRAF6-dependent pathway.
2.1.2. TRIF-dependent signalling
The adaptor TIR-domain-containing adaptor inducing IFN-b
(TRIF) is important in TLR3 and TLR4-dependent signalling
pathways (Fig. 2, blue frame). In addition to NF-kB and AP-1,
the TRIF-dependent pathway leads to the activation of the
Interferon Regulatory Factor (IRF)-3. TRIF-dependent activation
of NF-kB, AP-1 and IRF3 triggers the formation of an enhanceo-
some that permits the expression of IFN-b. Upon LPS stimulation,
[(Fig._2)TD$FIG]
Fig. 2. TLR-mediated signallingpathways.Upon ligand stimulation, all the TLRs, except theTLR3, recruit the adaptorMyD88. In turn,MyD88binds aprotein complex composedof
IRAK4, IRAK2 and TRAF6. TRAF6 self-polyubiquitinates resulting in the phosphorylation of TAK1. In turn, TAK1 activates the IKK complex that leads to the phosphorylation,
ubiquitination and degradation of IkBa. This allows NF-kB to translocate into the nucleus. Simultaneously, the TAK1-containing complex activates the MAP kinase pathway
triggering the activationof AP-1. Together, NF-kB andAP-1 induce the expression of pro-inﬂammatory cytokines. InpDCs, TLR7andTLR9 induce the activationofNF-kBandAP-1
through the classicalMyD88/IRAK4/IRAK2-dependentpathway. These TLRs also associatewithMyD88 toactivate IRF7.MyD88 formsamultiprotein complexwith IRAK4, TRAF6,
TRAF3, OPN-i, IKKa and IRAK1 that leads to the phosphorylation of IRF7. This allows its nuclear translocation and the induction of IFN-a expression. In addition toMyD88, some
TLRs recruitotheradaptorproteinsuponstimulation.TLR4andTLR2, in thecombinationwiththeTLR1or theTLR6, recruitTIRAPthat serves asa linkadaptor for the recruitmentof
MyD88. Moreover, TLR4 recruits a second link adaptor named TRAM that allows the interaction with the adaptor TRIF. Upon stimulation with agonist, TLR3 recruits TRIF, an
adaptor that interacts with a protein complex composed of TRADD, FADD and RIP-1 andwhich triggers the activation of NF-kB andAP-1. TRIF-mediated activation of NF-kB and
AP-1 also occurs through an IRAK2/TRAF6-dependent pathway. Upon stimulation, TRIF also binds TRAF3,which activates TBK1 and IKK-i. TBK1, alongwith IKK-I, phosphorylates
IRF3 and permits its homodimerization and nuclear translocation. IRF3, along with NF-kB and AP-1, cooperate to induce the expression of type I IFNs.
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adaptormolecule (TRAM)which allows the recruitment of the TRIF
and leads to the activation of the IRF3 [27] (Fig. 2). In response to
dsRNA challenge, TLR3 recruits the adaptor TRIF that interactswith
a complex composed of the Receptor-Interacting Protein kinase 1
(RIP1), the Tumor necrosis factor Receptor type 1-AssociatedDeath
Domain protein (TRADD) and the FAS-Associated death domain-
containing protein (FADD) (Fig. 2, blue frame). RIP1 undergoes
K63-linked polyubiquitination that permits the activation of TAK1,
which in turn activates NF-kB and AP-1 [28]. TRIF was also
reported to recruit a large complex that comprises TRAF6/TAB2/
TAB3/TAK1 (Fig. 2, cyan frame). As mentioned above, the activated
TAK1 induces the activation of the downstream IKK complex and
MAP kinases leading to nuclear translocation of the NF-kB and AP-
1 respectively. In this pathway, the activation of NF-kB and AP-1
involves IRAK2 and TRAF6 [25] instead of IRAK1 and IRAK4 [29,30]
(Fig. 2, cyan frame).
TRIF-dependent pathway also leads to the activation of IRF3.
TRIF interacts with the TNF Receptor-Associated Factor 3 (TRAF3)
to activate two non-canonical IKKs namely the TRAF family
member-associated NF-kB activator (TANK)-Binding Kinase 1
(TBK-1, also known as NAK or T2K) and the inducible IKK (IKK-I or
IKK-e) [14,15,31,32]. These two kinases phosphorylate IRF3,
leading to its homodimerization and allowing it to translocate
into the nucleus (Fig. 2, blue frame).
2.2. Viral recognition by TLRs
Viral nucleic acids, such as double-stranded RNA (dsRNA),
single-stranded RNA (ssRNA), unmethylated CpG rich motif (CpG-
DNA) and viral structural proteins, such as glycoproteins, are
considered as PAMPs and are recognized by some TLRs. Among
TLRs, only the endosomal ones, such as TLRs-3, -7, -8 and -9, are
involved in the detection of viral nucleic acids [20]. Indeed, viral
particles are endocytosed and degraded in late endosomes or
lysosomes. Therefore, viral DNA and RNA are released into these
intracellular acidic compartments, allowing viral nucleic acids to
be in close contact with endosomal TLRs. Furthermore, endosomal
localization of some TLRs is important to discriminate self nucleic
acids from non-self ones to avoid the induction of autoimmune
diseases. Only few TLRs were reported to play a role in the
recognition of DNA viruses and more particularly, only TLRs-2, -3
and -9 were shown to recognize Human Herpesviruses.
2.2.1. Role of TLR2 in Herpesvirus detection
TLR2 is expressed on the cell surface and recognizes
extracellular ligands. It is able to form heterodimers with either
TLR1 or TLR6 and has been shown to play a role in Herpesviruses
sensing. HSV-1 was shown to interact with TLR2 and this
interaction was described to be detrimental to its host. Indeed,
HSV-1 recognition by TLR2 induces the expression of inﬂamma-
tory cytokines in the brain that causes lethal encephalitis [33].
VZV was also demonstrated to activate the expression of
proinﬂammatory cytokines in a TLR2-dependent manner [34].
Finally, TLR2 and CD14 were reported to be involved in the
recognition of HCMV virions [35].
2.2.2. Role of TLR3 in Herpesvirus detection
Double-stranded RNA that is produced by most viruses during
their replicative cycle, is often considered as a PAMP [36]. RNA
viruses are important producers of dsRNA but surprisingly, only
some of them induce a TLR3-dependent innate immune response.
Indeed, some data have shown that, two ssRNA viruses, namely the
lymphocytic choriomeningitis virus (LCMV) and the vesicular
stomatitis virus (VSV), both known to produce dsRNA intermedi-
ates, did not induce any TLR3-dependent antiviral response [37].Although no role for TLR3 was pointed out in the recognition of
a DNA virus, the Murine cytomegalorvirus (MCMV) [37], TLR3 was
proposed to play a role in the antiviral response against other
Herpesviruses. Recent data demonstrated that TLR3 played an
important role in controlling the spread of HSV-1 within the
central nervous system. Indeed, Zhang et al. have described a
relationship between TLR3 and Herpes Simplex Encephalitis (HSE)
[38]. They observed that TLR3- and UNC-93B-deﬁcient patients,
that display an impaired activation of TLR3 signalling, were not
able to produce type I IFNs upon HSV-1 infection. This led to an
increased susceptibility to HSE and showed how important the
TLR3 is in neuronal protection against HSE. EBV was also shown to
elicit a TLR3-dependent pathway upon chronic active infection
[39]. Indeed, EBV was demonstrated to produce EBV-encoded
small RNA (EBER) that adopts a dsRNA-like conformation. This
EBER is abundantly present in EBV-infected cells and is released
during infection, which leads to the induction of type I IFNs
production in a TLR3-dependent manner. These ﬁndings are
consistent with those of Weber et al. who demonstrated that DNA
viruses could also produce dsRNA during their replicative cycle
[36].
2.2.3. Role of TLR9 in Herpesvirus detection
Like other TLRs involved in the recognition of nucleic acids,
TLR9 is expressed in endosomes. CpG DNA from viral and bacterial
origin, that possesses unmethylated CpG dinuclotides, is the best-
characterized ligand for TLR9 [14]. Similarly to bacterial DNA, HSV
DNA contains abundant CpG motifs that are responsible for TLR9
binding and subsequent IFN-a secretion [40]. It has been
demonstrated that the treatment with chloroquine, an inhibitor
of endosomal acidiﬁcation, inhibits HSV-2 recognition by TLR9
pointing out that an intact endocytic pathway was necessary to
induce TLR9-dependent signalling upon HSV-2 infection. Another
study also showed that HSV-1 viral replicationwas not required for
stimulation of TLR9/MyD88 pathway. This suggested that the
interaction between HSV-1 glycoproteins and cell surface recep-
tors may induce HSV-1 internalization and subsequent release of
viral DNA in the endosomal compartment, allowing the interaction
with TLR9 [41].
3. Cytoplasmic pathogen recognition receptors
As mentioned above, TLRs are involved in the recognition of
either extracellular or endosomal microbial components whereas
other classes of PRRs are involved in the recognition of pathogens
that invade host cytosol. Among these cytosolic PRRs, the RIG-I-
Like Receptors (RLRs), the NOD-Like Receptors (NLRs), the DAI and
the AIM2 are the best-characterized.
3.1. RIG-I-like receptors
RLRs consist in a group of cytosolic RNA helicases that are
expressed in most cell types and are involved in the recognition of
viral RNA. This group encompasses three members which are
Retinoic acid-Inducible Gene I (RIG-I) [42], Melanoma Differentia-
tion-Associated gene 5 (MDA5) [43], and Laboratory of Genetics
and Physiology-2 (LGP-2) [44]. RIG-I is characterized by two N-
terminal Caspase-Recruitment Domains (CARDs), a DExD/H box
RNA helicase domain and a C-terminal Repressor Domain (RD)
(Fig. 4). The helicase and the RD domains of RIG-I are involved in
the recognition of viral RNA whereas the CARDs are important for
triggering the downstream signalling. In resting cells, the RD
interacts with the helicase domain to mask the CARDs rendering
RIG-I inactive. Upon interaction with its agonist, RIG-I undergoes
conformational changes leading to CARDs exposition and activa-
tion of the downstream signalling (Fig. 4).
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Fig. 3. Schematic representation of the protein structure of the RIG-Like Receptors
family. RLRs consist in a group of cytosolic RNA helicases that comprises three
members namely RIG-I, MDA5 and LGP2. RIG-I and MDA5 are composed of two
amino-terminal CARD domains and a central Helicase domain. Contrary to RIG-I,
MAD5 lacks the C-terminal repressor domain (RD). LGP2 only possesses the central
Helicase domain.
P. Vandevenne et al. / Biochemical Pharmacology 80 (2010) 1955–19721960Like RIG-I, MDA5 contains two CARD domains and a RNA
helicase domain. However it lacks the C-terminal Repressor
Domain [43] (Fig. 3). In contrast, LGP-2 comprises no CARD
domains and was originally found to function as a dominant-
negative regulator of RIG-I/MDA5-mediated signalling [43,44]
(Fig. 3). However, a recent study demonstrated that LGP-2 is
required for RIG-I- and MDA5-mediated antiviral response and
acts as a positive rather than a negative regulator of RIG-I/MDA5-
mediated antiviral response [45]. Therefore, the role of LGP-2 in
antiviral response still remains controversial.
3.1.1. RLRs signalling pathways
The activation of RLR-dependent signalling pathway leads to
the activation of two important transcription factors, namely NF-
kB and IRF3, that induce along with AP-1, the expression of IFN-b
[15]. As TLRs do, RLRs interact with adaptor proteins such as MAVS
and MITA allowing the recruitment of downstream effectors
(Fig. 5).
In 2005, a new component of the RIG-I/MDA5 signalling was
simultaneously discovered by four different laboratories [46–49].
This new protein named Mitochondrial Antiviral Signalling
(MAVS), also termed Interferon-b Promoter Stimulator 1 (IPS-1),
Virus-Induced Signalling Adaptor (VISA) or CARD adapter inducing
IFN-b (Cardif), operates downstream of RIG-I/MDA5 and upstream
of the IKK complex and TBK1/IKK-I. Therefore, MAVS has been
characterized as an adaptor for RLRs that regulates the activation of
NF-kB and IRF3 (Fig. 5). MAVS contains two TRAF binding motifs
(TIM) and a N-terminal CARD-like domain allowing interaction
with the TRAF proteins and the CARDs from RIG-I/MDA5
respectively [46,48]. MAVS also possesses a C-terminal mitochon-
drial transmembrane (TM) domain that targets the protein to the
outer membrane of the mitochondria [46]. The mitochondrial
localization of MAVS is essential for its function in the antiviral
response since the deletion of the TMdomain completely abolishes
its signalling function [46].
Viral RNA recognition by RIG-I and/or MDA5 allows their CARD
domains to interact with the one of MAVS and triggers the
formation of two large complexes that both contain the TRADD
protein. The ﬁrst complex comprises TRADD, FADD and RIP-1
(Fig. 5). Altogether, these proteins form the TRADDosome that
regulates the activation NF-kB [50]. When the RLRs detect viral
RNA and consequently interact with MAVS, TRADD gets recruited.
In turn, TRADD associates with FADD and RIP-1. This association is
mediated through DD (Death Domain) homotypic interactions.
Within this TRADDosome, RIP-1 is K63-linked polyubiquitinated
by TRAF2 and TRAF3 that are also recruited to MAVS. This
[(Fig._4)TD$FIG]Fig. 4. Schematic representation of RIG-I activation. In resting cells, RIG-I exists as an ina
and Helicase domains. Upon viral infection, 50-ppp dsRNA is produced and binds the RD d
exposed in the presence of ATP. Therefore, RIG-I is active and the freed CARDs are able tmodiﬁcation results in the activation of the IKK complex and
subsequent activation of NF-kB [50]. FADD also interacts with
caspase-8 and -10 through DED (Death Effector Domain) homo-
typic interactions to regulate the activation of NF-kB. In the
absence of the inhibitor FLIP, caspase-8 induces cell death (Fig. 5).
The second complex that is formed upon MAVS recruitment to
RLRs comprises TRADD, TRAF3 and TANK (Fig. 5). This complex
leads to the activation of TBK1 which in turn causes the
phosphorylation of IRF3, its dimerization and its nuclear translo-
cation [50].
In addition to MAVS, another adaptor protein was recently
discovered and namedMediator of IRF3 Activation (MITA). It is also
known as Stimulator of Interferon Genes (STING) or Endoplasmic
Reticulum IFN Stimulator (ERIS) [51–54]. MITA was found to be
essential for RIG-I-mediated signalling pathway but dispensable
for MDA5-dependent immune response upon dsDNA stimulation
[55]. MITA was ﬁrstly reported to be expressed at the outer
membrane of mitochondria [54] but recent reports showed that
MITA is rather expressed in the endoplasmic reticulum [51,52,54].
The discrepancy observed in the localization ofMITAwas due to its
associationwithmicrosomes, a complex of continuousmembranes
that comprise the ER, Golgi and transport vesicles [55]. To reinforce
the ER localization of MITA, co-immunoprecipitation experiments
have shown that MITA associates with TRAPb, a component of the
Translocon-Associated Protein (TRAP) complex, required for
protein translocation across the ER membrane following transla-
tion. MITA also interacts with SEC61b, a translocon adaptor [51].
These ﬁndings suggest that MITA could be involved in translocon
function, which may facilitate the induction of type I IFNs. Inctive form in which the C-terminal repressor domain (RD) interacts with both CARD
omain of RIG-I which leads to a conformational change and allows the CARDs to be
o recruit and interact with the adaptor MAVS to trigger the downstream signalling.
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Fig. 5. RLRs-mediated signalling pathway. Upon infection, viral RNA binds RIG-I or MDA-5 which in turn recruits the adaptor proteinMAVS via CARD homotypic interactions.
Then,MAVS associateswith, TRAF2, TRAF3 and alsowith TRADD leading to the formation of a large complex called the TRADDosomes. In this complex, TRADD associates with
FADD and RIP-1. Ubiquitination of RIP-1 by TRAF2 and TRAF3whithin the TRADDosome induces the activation of NF-kBwhich is also controlled by caspases-8 and -10 in the
presence of FLIP. TRADD also associates with TRAF3 and TANK controlling the activation of IRF3. Upon dsDNA stimulation, MITA, which is expressed in the ER, interacts with
both RIG-I and TBK1 allowing the activation of IRF3 activation.
P. Vandevenne et al. / Biochemical Pharmacology 80 (2010) 1955–1972 1961addition, MITA was also found in association with RIG-I and TBK1
(Fig. 5). So, MITA might allow RIG-I-mediated detection of viral
trancripts as well as dsDNA at the intersection of ribosome/ER
translocon [51]. Furthermore, phosphorylation of MITA at Ser358
by TBK1 has been shown to constitute a critical step for subsequent
virus-triggered activation of IRF3 [54].Recently, the role of the DEAD-box helicase, DDX3 (also known
as DDX3X) in the activation of IFN-b has been pointed out [56,57].
DDX3 was shown to interact with IKKe upon viral infection [57]
but it was also found to be a substrate of TBK1. Indeed, TBK1-
dependent phosphorylation induces DDX3 nuclear translocation
and binding on target promoter where it activates the expression
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Fig. 6. Schematic overview of the RIG-I/MDA-5 discrimination among viral ligands. RIG-I is preferentially involved in the detection of viral 50-ppp dsRNA and short dsRNA
whereasMDA-5 is more sensitive to capped viral ssRNA and long dsRNA. Moreover, RIG-I andMDA-5 recognize different ssRNA viruses to induce appropriate innate immune
responses.
P. Vandevenne et al. / Biochemical Pharmacology 80 (2010) 1955–19721962of IFN-b [56]. In addition, DDX3 was also shown to bind stem-loop
RNA of viral origin but also the CARD of MAVS and the RD of RIG-I
through its C-terminal domain [58]. It was suggested that DDX3
may be required for initial sensing of viral RNA and facilitates
MAVS-dependent signalling [58]. Taken together, these new
ﬁndings suggest that DDX3 acts as an enhancer IFN-b expression
upon RLRs stimulation.
3.1.2. Viral recognition by RLRs
As mentioned above, RIG-I and MDA5 are able to activate
similar pathways. Interestingly, recent studies have shown that
these two RLRs recognize different ssRNA viruses, pointing out that
RIG-I and MDA5 can discriminate among different ligands toinduce an appropriate innate immune response to RNA viruses
(Fig. 6).
RIG-I was demonstrated to be important for the recognition of
in vitro transcribed RNA [59]. Independently, two groups reported
that viral ssRNA bearing a 50-triphosphate (50-PPP) end was a
ligand for RIG-I [60,61] but recent studies opposed that in vitro
transcribed RNA bearing only a 50-triphosphate moiety was not
sufﬁcient to induce the activation of RIG-I. It was proven that only
stem-loop RNA species bearing a 50-triphosphate end stimulated
the immune system [62,63]. In addition, it was published that the
viral genome of the Sendai and Inﬂuenza A viruses rather than their
transcripts, could activate type I IFN response through a RIG-I-
dependent pathway [64]. This suggests that the single-stranded
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Fig. 7. Schematic representation of the protein structure of the NOD-Like Receptors
family. NLR are composed of a central NACHT Nucelotide-Binding Domain (NBD)
and a C-terminal LRR domain involved in the recognition of pathogens. Their N-
terminal domain can be either a CARD or a PYD domain. The NLRP subfamily
constitutes the largest group among the NLR family and is characterized by an N-
terminal PYD domain. The best-described NLRP members are NLRP1 and NLRP3
which play an essential role in the inﬂammasome. The NLRC subfamily comprises
only ﬁve members and is characterized by an N-terminal CARD domain. NOD1 and
NOD2 are the best-described members within NLRC subfamily.
P. Vandevenne et al. / Biochemical Pharmacology 80 (2010) 1955–1972 1963genome from RNA viruses such as these two viruses could adopt a
‘‘panhandle’’ conformation by pairing of complementary 50 and 30
ends, allowing the activation of RIG-I. Altogether, these new
ﬁndings suggest that RNA secondary structures with the combi-
nation of a 50-triphosphate end seem to be sufﬁcient to induce RIG-
I activation and subsequent induction of type I IFNs expression.
MDA5was shown to bemore sensitive to synthetic dsRNA such
as poly(I:C) [59,65]. Furthermore, a recent study provided
evidences for discrimination of dsRNA by RLRs based on the
length of these dsRNA [66]. So, RIG-I was found to be more
sensitive to short dsRNAwhereasMDA5 especially recognizes long
dsRNA.
In addition to RNA viruses, RLRs have also shown to be involved
in the recognition of DNA viruses. Previous studies proved that
HSV-1 induced type I IFNs expression through a mechanism
dependent both on RIG-I and the adaptor MAVS [67,68].
Furthermore, it has been reported that MITA induced a robust
expression of type I IFNs upon DNA stimulation or HSV-1 infection
[51,55]. A new report has demonstrated that viral dsDNA serves as
a template for RNA polymerase III (POL3) which converts DNA into
RNA bearing a 50-triphosphate moiety which is able to stimulate
RIG-I [69]. It has been reported that HSV-1-induced expression of
IFN-b was impaired upon treatment with a speciﬁc inhibitor or
siRNA against POL3. These new ﬁndings suggest that POL3 could
act as a DNA sensor leading to the expression of IFN-b in a RIG-I-
dependent manner upon HSV-1 infection [69]. Epstein-Barr virus
(EBV) was also found to induce a POL3/RIG-I-dependent signalling
pathway. As already mentioned, EBV encodes EBERs that are
noncoding and nonpolyadenylated RNAs able to form stem-loop
structure leading to the formation of dsRNA molecules [70].
Similarly, EBER1 and EBER2 are transcribed by RNA polymerase III
that synthesizes RNAs containing a 50-triphosphate end that are
therefore, able to activate RIG-I-dependent signalling pathways.
3.2. NLRs
Nucleotide Oligomerization Domain (NOD)-like receptors
(NLRs) are cytoplasmic PRRs that recognize PAMPs able to induce
innate immune responses. The human NLR family comprises more
than 20 members that are divided in two main subfamilies
according to their N-terminal domain (Fig. 7). NLRs share a central
NACHT Nucelotide-Binding Domain (NBD) and a C-terminal LRR
domain involved in the recognition of pathogens. However, they
differ from each other in their N-terminal domains that can be
either a CARD or a Pyrin Domain (PYD) [71,72]. Therefore, NLRs
that contain a CARD are part of the NLRC subfamily, whereas NLRs
that possess a PYD form the NLRP subfamily (also known as NALP).
While the NLRC subfamily comprises ﬁve members, the NLRP
subfamily constitutes a large group of 14 members. The best-
described NLRP members are NLRP1 (also known as NALP1) and
NLRP3 (also known as NALP3). Similarly, the best-characterized
NLRC members are NOD1 (also known as NLRC1), NOD2 (also
known as NLRC2) and NLRC4 (Fig. 7). NLRP3 is essentially involved
in the activation of the inﬂammasome. By contrast, NOD2 rather
plays a role in the activation of NF-kB and MAP kinase pathways.
The production of IL-1b bymacrophages andmonocytes plays also
an important role in the innate immune response during the viral
infection. Expression of mature IL-1b results from the cleavage of
pro-IL-1b by caspase-1 which is preliminary activated by a
multiprotein complex called inﬂammasome and regulated byNLRs
[73].
3.2.1. NLR-mediated inﬂammasome
To date, among the NLR family, only NLRP1, NLRP3 and NLRC4
are known to activate the inﬂammasome that leads to the cleavage
of pro-form of the IL-1b in response to microbes [71,74].The well-described NLRP3 inﬂammasome is activated by many
stimuli from both bacterial and viral origin and requires two
signals to induce the production of mature IL-1b [72] (Fig. 8). The
ﬁrst signal comes frommicrobial PAMPs such as LPS, bacterial and
viral RNA, dsRNA, dsDNA and MDP, each recognized by its speciﬁc
receptor which in turn induces the production of pro-IL-1b. The
second signal is the result of the presence of awide range of Danger
Associated Molecular Patterns (DAMPs) including (i) pore forma-
tion, (ii) ROS production as well as (iii) lysosome damages
[71,74,75]. In response to these DAMPs, NLRP3 recruits the
adaptor Apoptosis-associated Speck-like protein containing a
CARD (ASC) via PYD homotypic interactions. In turn, ASC recruits
the pro-caspase-1 through its CARD domain. Once matured by a
catalytic process, caspase-1 homodimerizes and induces the
processing of the pro-IL-1b into biologically active IL-1b that is
secreted outside the cell where it induces inﬂammatory responses.
3.2.2. Viral recognition by NLRs
Although NLRs were initially described to play a role in innate
immunity against bacteria [75,76], they have been recently
involved in immune response to viral infection. There are several
evidences showing that infection with Adenovirus, Inﬂuenza A
virus and Modiﬁed Vaccinia Ankara (MVA) induces the activation
of NLRP3-dependent inﬂammasome [9,77–80]. Similarly, in
addition to its role in the detection of bacterial muramyl dipeptide
(MDP), NOD2 was shown to induce a MAVS/IRF3-dependent
signalling upon infectionwith the Respiratory Syncitial Virus (RSV)
[81,82].
3.3. AIM2
In 2009, two teams independently discovered a new receptor
for DNA that was called AIM2 (Absent In Melanoma 2) and that
belongs to the interferon-inducible (IFI) family. AIM2 binds
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Fig. 8. Schematic overview of the NLRP3-mediated inﬂammasome. SomeNLRs can form amultiprotein complex called inﬂammasome. NLRP3-mediated inﬂammasome is the
best-characterized and its activation requires two signals. The ﬁrst signal comes from a PAMP recognized by a speciﬁc PRR that triggers the activation of NF-kB and therefore
allows Pro-IL-1b synthesis. The second signal is induced by DAMPs such as K+ efﬂux, ROS production and lysosome damages that are produced during the infection. These
DAMPs are then recognized by NLRP3, which, in turn, recruits the adaptor ASC through PYD homotypic interaction. ASC interacts with the pro-caspsase-1 which becomes
activated and allows the cleavage of pro-IL-1b into biologically active IL-1b that is released outside the cell.
P. Vandevenne et al. / Biochemical Pharmacology 80 (2010) 1955–19721964cytosolic dsDNA via its HIN domain, whereas its PYD domain can
form homotypic interactions with the adaptor ASC. This forms a
new inﬂammasome complex that activates caspase-1 and subse-
quent cleavage of pro-IL-1b into IL-1b [7,8] (Fig. 9).
3.3.1. Viral recognition by AIM2
Evidences showed that AIM2 induces caspase-1 activation and
IL-1b production in response to dsDNA from both bacterial and
viral origin such as vaccinia virus and murine cytomegalovirus
[83,84].
3.4. DAI
During infection, nucleic acids, such as DNA derived from
pathogens and/or damaged host cells are released and can meet
sensors in the cytosol. This triggers the activation of innate
immune responses. In addition to TLR9 that recognizes CpG DNA
from both bacterial and viral origin, a new cytosolic receptor
termed DAI (also known as ZBP-1) was found to bind B-form
dsDNA leading to the activation of IRF3 which participates in the
induction of IFN-b expression [5]. Additionally, B-form dsDNAwas
reported to stimulate immune response. Intracellular administra-tion of B-form dsDNA, but not Z-form dsDNA, triggers the
induction of type I IFNs in a MAVS/TBK1/IRF3-rather than in a
TLR-dependent pathway [85]. Additional works showed that DAI
directly interacted with DNA through its D3 region followed by
oligomerization of DAI. Once oligomerized, DAI is able to recruit
TBK1 and IRF3 leading to the activation of downstream signalling
pathway [86]. There are accumulating data demonstrating that
additional cytosolic DNA sensor(s) may exist(s) since DAI
knockdown by RNAi abrogates type I IFNs expression upon B-
formdsDNA stimulation in L929 and RAW264.7 cell lines but not in
MEFs cells. This suggests that another DNA sensor exists in this cell
line [5,86].
3.4.1. Viral recognition by DAI
DAI was found to contribute in mounting an innate immune
response during infection with DNA viruses such as HSV-1 but not
with ssRNA viruses such as the Newcastle disease virus (NDV) [5].
A more recent study also demonstrated that DAI was essential for
the activation of IRF3 and so for the expression of IFN-b in the
context of HCMV infection [87]. In addition, it has been shown that
DAI-dependent activation of IRF3 required the adaptor MITA
following HCMV infection [87].
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Fig. 9. Schematic representation of the AIM2-dependent inﬂammasome. AIM2 binds dsDNA from bacterial and viral origin but also host dsDNA. AIM2-dependent
inﬂammasome requires two signals. The ﬁrst signal comes from the pathogen (virus or bacteria) that triggers PRR-dependent signalling pathway and allows pro-IL-1b
production. During the infection, dsDNA is released and gets in close contact with AIM2 in the cytosol. AIM2 then recruits the adaptor ASC through their respective PYD
domain. ASC, in turn, interacts with pro-caspase-1, which is then cleaved and becomes active allowing the processing of pro-IL-1b into mature IL-1b.
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other pathogens occurs in two waves. Type I IFNs production in
response to PAMPs detection by host PRRs constitutes the the ﬁrst
wave of genes to be expressed. Type I IFNs expression is
responsible for the induction of the second wave of genes, the
Interferon-Stimulated Genes (ISGs) that encode antiviral effectors
which allow the clearance of pathogens.
4. Type I interferon-dependent signalling pathway and
antiviral actions
Interferons were ﬁrst discovered by Isaacs and Lindemann in
1957 [88,89]. They found that IFNs are secreted by virally-
infected cells and induce an antiviral state able to limit the
propagation of the virus. Moreover, it was shown that IFNs have
both autocrine and paracrine effects which enable the induction
of an antiviral state both in the infected cell and in the
neighbouring non-infected cells [89–92]. IFNs are classiﬁed in
three types: (i) Type I IFNs include IFN-a and IFN-b. They are
directly induced in response to viral infection and produced by
innate immune cells such as dendritic cells and macrophages but
they can also be encountered in ﬁbroblasts. (ii) Type II IFN only
comprises IFN-g member that is produced by NK cells and by
activated T cells. (iii) Type III IFNs were more recently described
and include IFN-l1, -l2, -l3 also known as IL-29, IL-28A and IL-
28B, respectively [90]. Type III IFNs are directly produced in
response to viral infection.
Type I IFNs (IFN-a/-b) play a key role in the activation of the
antiviral response. They are responsible for the activation of the
Jak/STAT pathway that leads to the expression of ISGs that encode
antiviral effectors.4.1. Type I IFN signalling pathway
In response to PAMPs, host PRRs activate NF-kB, AP-1, IRF3.
These transcription factors then cooperate to induce the expres-
sion of type I IFNs. IFN-a and -b are released in the extracellular
medium and bind to their cognate receptors which are composed
of two subunits, namely the Interferon-Alpha/Beta Receptors
(IFNAR) 1 and 2 (Fig. 10). The binding leads to the induction of the
antiviral response through the initiation of the Jak/STAT pathway.
Thus, IFN binding to IFNAR1 and IFNAR2 allows the activation of
the receptor-associated kinases Jak-1 and Tyk-2 that are respec-
tively associated to IFNAR2 and IFNAR1 (Fig. 10). Subsequently,
Jak-1 and Tyk-2 respectively phosphorylate STAT1 and STAT2 that
can heterodimerize and associate with an additional protein, p48
(also known as IRF9). This complex, named interferon-stimulated
gene factor 3 (ISGF-3), then translocates into the nucleus where it
can activate the expression of ISGs possessing a cis-acting DNA
element termed ISRE in their promoter [89–91]. Among the ISG
proteins, the best-characterized are PKR, ISG15, Mx proteins and
OAS1. By targeting different cellular processes, such as the
messenger RNA transcription and the protein translation and by
inducing the degradation of viral products, ISGs inhibit the
assembly of virions therefore limiting the viral spread [88].
5. Strategies used by Human Herpesviruses to subvert the
innate immune response
Viruses are considered as obligate parasites that exploit their
host’s cellular machinery for their own beneﬁt. Therefore, it is
important for them to develop strategies to escape antiviral
responses activated by their host. Since IFNs are key players in the
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Fig. 10. Schematic representation of PRRs and type I IFN pathways. During viral infection, a two-wave antiviral response takes place. During the ﬁrst wave, PRRs recognize
viral PAMPs such as dsRNA, dsDNA, ssRNA and 50-ppp ssRNA and trigger signalling pathways that activate the threemain transcription factors namely, NF-kB, IRF3 and AP-1.
Those transcription factors cooperate to induce the expression of IFNb that is secreted. In response to TLR7 and TLR9 stimulation, IRF7 can also be activatedwhich leads to the
expression and the release of IFN-a. During the secondwave, IFN-a/-b bind their cognate receptors composed of the subunits IFNAR1 and IFNAR2. Following the binding, the
signal is transduced to the associated-receptor kinases Jak1 and Tyk2 that respectively phosphorylate STAT1 and STAT2. Phosphorylated STAT1 and STAT2 heterodimerize
and associate with p48 (also known as IRF9) to form a complex called ISGF-3. This complex translocates into the nucleus to induce the expression of ISGs encoding antiviral
effectors such as ISG15, PKR, Mx proteins and OAS1 and allow the establishment of an antiviral state in the infected cells as well as in neighbouring non-infected cells.
P. Vandevenne et al. / Biochemical Pharmacology 80 (2010) 1955–1972966activation of antiviral responses, most viruses have elaborated a
wide range of molecular mechanisms targeting the PRRs- and IFN-
dependent signalling pathways, so that they can reduce the
expression of IFNs and ISGs, respectively. In this last chapter, we
will describe strategies used by Human Herpesviruses (i.e. HSV-1,
VZV, HCMV and EBV) to subvert innate immune responses. These
later are summarized in Table 2 and depicted in Fig. 11.5.1. The Alphaherpsevirinae
5.1.1. Herpes simplex virus 1 (HSV-1)
During the primary infection, HSV-1 productively infects
mucoepithelial cells. After this, it establishes a lifelong latency
in its host’s neurons andmany years later, in response to stress, UV
exposition or immune weakness, the virus can reactivate from
Table 2
Herpesvirus-encoded proteins involved in viral interference.
Herpesvirus Viral proteins Cellular targets Effects
HSV-1 ICP34.5 eIF-2a Induces eIF-2a dephosphorylation
ICP34.5 TBK1 Prevents IRF3 activation and subsequent expression of type I IFNs
ICP0 IRF3 Inhibtis IRF3 nuclear accumulation and subsequent induction of type I IFN
ICP27 STAT-1a Inhibits STAT-1a phosphorylation and the subsequent nuclear translocation and ISGs expression
Us11 OAS Prevents the production of 20 ,50-oligoadenylate and the subsequent activation of latent RNase L
Vhs mRNA Induces the degradation of cellular and viral mRNA
VZV ? Jak2, STAT-1a Induces the degradation of Jak2, STAT-1a and subsequent downregulation of MHC II expression
? Golgi-Cell surface
trafﬁcking
Induces a downregulation of MHC I expression at the cell surface
? NF-kB pathway Downregulates of pro-inﬂammatory cytokines expression
Unknown viral
secreted factor?
IFNa production Impairs the establishment of the antiviral state
HCMV pp65 (ppUL83)
(still controversial?)
IRF3 Affects the phosphorylation of IRF3 and the subsequent nuclear translocation and IFN-b expression
Immediate-early
protein 2 IE86
NF-kB Blocks NF-kB binding activity to DNA and the subsequent production of IFN-b
? Jak1, p48 Donwregulates MHC I expression, disrupts the ISGF3 complex and inhibits the expression of ISGs
EBV BZLF-1 IRF7 IFN-a4, IFN-b, Tap2 downrexpression
LF2 IRF7 Prevents IRF7 dimerization and subsequent inhibition of target genes expression
BGLF4 IRF3 Prevents IRF3 from IFN-b binding to the promoter
BRLF1 IRF3, IRF7 Decreases the level of IRF3 and IRF7, leading to an inhibition of IFN-b expression
LMP2A/LMP2B IFN receptors Downregulates type I/II interferon receptors (IFNRs)-mediated signalling
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can also be associated with severe encephalitis. Although HSV-1
rapidly elicits an innate immune response through the activation
of IRF3 [93], it has developed various mechanisms to escape its
host innate immune responses and increased its capacity to
replicate and to persist. Numerous studies demonstrated that HSV-
1 encodes proteins that target the IRF3 pathway, IFN production
and downstream signalling [94–96] (Fig. 11). Among these
proteins, ICP34.5, ICP0, ICP27, Us11 and Vhs, have antiviral
functions.
5.1.1.1. ICP34.5. ICP34.5 is referred to as a late gene which is
already detected during the early phase and whose expression
signiﬁcantly increases during later phase of the viral infection.
Thanks to its ability to interact with PP1a, ICP34.5 was ﬁrst
described to dephosphorylate eIF-2a whose phospohrylation is
induced by PKR in response to HSV-1 infection, thus sustaining
protein synthesis [97–99]. ICP34.5-mediated dephosphorylation of
eIF-2a also leads to the inhibition of autophagy and other cellular
stress responses [98]. Moreover, ICP34.5 has been recently
demonstrated to form a complex with TBK1 thereby disrupting
the interaction between TBK1 and IRF3 and the subsequent
induction of IFN-b expression [100].
5.1.1.2. ICP0. ICP0 is an immediate-early protein which plays an
important role during HSV-1 replication, latency and reactivation.
It is characterized by a RING-ﬁnger domain that does not bind DNA
but rather acts as an E3 ubiquitin-like ligase required for the
degradation of target proteins. It was previously demonstrated
that the expression of ICP0 during HSV-1 infection inhibits the
induction of ISGs by targeting IRF3 activation [101]. While this
inhibition is thought to require a functional RING-ﬁnger domain
and proteosomal activity [101], no degradation of known
components of the IRF3 pathway protagonists such as TBK1, IKKe,
IRF3 and CBP has ever been observed [101,102]. In a coinfection
model, the IFN-b production mediated by the Sendai Virus was
demonstrated to be abrogated upon HSV-1 infection [103]. In this
model, ICP0 was also found to accelerate the IRF3 degradation
upon activation, thereby affecting its nuclear accumulation [103].
Another study revealed that ICP0 rapidly sequesters the activated
IRF3 and CBP/p300, forming nuclear ICP0-containing foci visible by
confocal microscopy. This keeps them away from activating IFN-bgene transcription [104]. More recently, the cytoplasmic localiza-
tion of ICP0 has been reported to inhibit the activation of IRF3
[105]. In this context, it was shown that the inhibitory effects of
ICP0 did not require its E3 ubiquitin ligase activity. Therefore it
appears that, upon HSV-1 infection ICP0 inhibits the nuclear
accumulation of IRF3 and that the inhibitory effect of ICP0 does not
require the E3 ubiquitin ligase activity.
5.1.1.3. ICP27. ICP27 is an immediate early proteinwhich exerts an
important role in the induction of viral gene expression and in the
export of viral mRNA [97]. It was also described as an antagonist of
the antiviral response. Indeed, Melchjorsen and colleagues
demonstrated that ICP27-null infected macrophages produced
higher amounts of IFNs and other cytokines compared to wt-
infected ones [106]. Similarly, macrophages infected with the
IC27-mutant resulted in a stronger activation of IRF3 and NF-kB
than those infected with the wt virus [106]. ICP27 was also
reported to inhibit STAT-1 phosphorylation and nuclear accumu-
lation upon IFN-a treatment during HSV-1 infection. Thereby it is
able to inhibit IFNa-dependent signalling [107]. Recently, ICP27
expression has been demonstrated to induce the secretion of a
soluble factor. This factor acts by inhibiting STAT-1 nuclear
translocation upon IFN-a treatment and so, it prevents the
subsequent expression of ISGs [108].
5.1.1.4. Us11. Us11 is a late protein able to interfere with the
antiviral response due to HSV-1 infection. Indeed, Cassady and
colleagues showed that the expression of Us11 earlier in the lytic
cycle and prior the HSV-1-mediated PKR phosphorylation, allows
the binding of Us11 to PKR. This prevents the phosphorylation of
eIF-2a and thereby precludes the inhibition of viral transcripts
translation [109]. More recently, Us11 has been reported to block
the activation of oligoadenylate synthase (OAS) impairing the
production of 20,50-oligoadenylate and the subsequent activation
of the latent RNase L [110]. Consequently, Us11 was found to
counteract the host defence by inhibiting the virus-induced RNA
degradation.
5.1.1.5. Vhs. The virion host shutoff protein (vhs) is encoded by the
UL41 gene and has an endoribonuclease activity. Vhs is expressed
during the late phase of the lytic cycle and incorporated into the
virion. It possesses the ability to shutoff cellular proteins synthesis
[(Fig._11)TD$FIG]
Fig. 11. Schematic overview of herpesviruses interference with the immune response. Herpesviruses encode proteins that interfere with both PRRs- and type I IFNs signalling
pathways. The cellular targets are depictedwith colored bars. HSV-1 interference is represented as green bars, VZV as orange bars, HCMV as bleu bars and EBV as purple bars.
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been described to interfere with both type I and type II IFN-
dependent signalling pathways by accelerating degradation of ISGs
mRNAs [97].
5.1.2. Varicella-zoster virus (VZV)
VZV is a common virus responsible for two well known
diseases: varicella and zoster. Varicella (i.e. chicken pox) is the
disease resulting from the primary infection in skinwhereas Zoster
(i.e. shingles) occurs when the virus reactivates from its latency in
the dorsal root ganglia. Although, to date little is known about the
activation of IRFs by VZV and the subsequent induction of type I
IFNs, VZV was also described to possess mechanisms to avoid
immune surveillance (Fig. 11). It has been for example demon-
strated to downregulate class I and II MHC protein expression
[113,114]. Indeed, VZV induces the retention of class I MHCmolecules in the Golgi apparatus, leading to a decrease of the cell-
surface expression [114] and it reduces the level of Jak2 and STAT-
1a proteins, thereby inhibiting the expression of class II MHC
molecules at the cell surface [113]. Additional studies revealed that
VZV inhibits NF-kB activation during viral infection [115,116].
Since it induces a very transient translocation of p65/p50 NF-kB
heterodimers into the nucleus, it was shown that p65 and p50 are
rapidly resequestered in the cytoplasm by IkBawhose expression
is stabilized during VZV infection [115]. Therefore, by trapping NF-
kB, stabilized IkBa prevents the nuclear accumulation of NF-kB
heterodimers and limits the expression of target genes and the
subsequent innate immune response activation. In addition, our
team recently demonstrated that VZV inhibits the expression of
ICAM-1 in response to TNFa treatment [116]. We showed that this
down-regulation is due to an inhibition of NF-kB activation.
We observed that the nuclear translocation of the p50 but not p65
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infection. This leads to a disruption of the p65/p50 heterodimers
that, consequently, cannot bind their target promoters anymore
such as this of icam-1 [116]. Therefore, by modulating the
recruitment of NF-kB on selected cellular promoters, VZV is able
to interfere with the innate immune response mediated by this
transcription factor. A recent study in primary plasmacytoid
dendritic cells (pDCs) revealed that these cells are impaired in IFN-
a production following VZV infection [117]. Furthermore, the
authors observed that the mixed culture of VZV-infected and non-
infected pDCs avoid IFN-a expression by non-infected pDCs upon
stimulation with ODN2216 [117]. This suggests the existence of a
secreted factor by the VZV-infected cells that could impair the non-
infected cells in producing IFN-a, consequently this indicates that
VZV inhibits the capacity of pDCs to express this host defence
cytokine.
5.2. The Betaherpesvirinae
5.2.1. Human cytomegalovirus (HCMV)
HCMV is a ubiquitous pathogen that causes signiﬁcant
morbidity and mortality in humans. It is considered as life-
threatening for immunocompromised patients such as those
suffering from AIDS, organ transplant recipients or neonates.
During primary infection, HCMV productively infects monocytes,
lymphocytes and epithelial cells. After primary infection, As other
members of its family, HCMV enters in latency that occurs in
monocytes and lymphocytes. Similarly to HSV-1, HCMV infection
rapidly induces the activation of IRF3 and leads to the expression of
IFNs and ISGs [93,118,119]. In this context, HCMV-mediated
activation of IRF3 was shown to be dependent on the glycoprotein
gB-mediated fusion with the cell membrane, rather than on de
novo synthesis of viral proteins [118]. Although HCMV was found
to rapidly induce the activation of IRF3, the virus rapidly abrogated
host’s immune responses (Fig. 11).
5.2.1.1. pp65. Abate and colleagues identiﬁed the major viral
structural protein pp65 encoded by the UL83 gene as a protein able
to counteract the antiviral response activated upon virus binding
and penetration [120]. Although pp65 was ﬁrstly reported to
dephosphorylate IRF3 affecting its subsequent nuclear transloca-
tion [120], the role of pp65 in the inhibition of IRF3 activation still
remains ambiguous. Indeed, it was shown that infection with a
deletion mutant virus for the UL83 gene (DUL83 virus) induced a
strong accumulation of IFN-bmRNAwhereas infectionwith a virus
possessing a stop codon in the UL83 gene (UL83Stop virus)
completely blocked the induction of IFN-b as the wt virus did
[121]. It appeared that the deletion of the entire UL83 gene alters
the expression of the pp71 protein, an important regulator of
immediate-early gene expression. This alteration induced a delay
in the expression of IE86 which is responsible for the inhibition of
IFN-b expression [121]. Consequently, IE86 rather than pp65, is
responsible for HCMV’s immune evasion.
5.2.1.2. IE86. HCMV’s viral protein IE86 is encoded by the immedi-
ate-early 2 (IE2) gene that, as described above, acts as an IFN-b
antagonist. Although IE86 expression was not shown to alter the
phosphorylation nor the dimerization and nuclear translocation of
IRF3 [122], IE86 expression was reported to block the expression of
chemokines such as RANTES, MIP-1a and IL-8 by inhibiting NF-kB
activation [121,123]. Consequently, this suggested that the down-
regulation of IFN-b expressionby IE86uponHCMV infectionmaybe
rather due to the inhibition of NF-kB than IRF3.
5.2.1.3. Disruption of IFN-a signal transduction pathway by HCMV. It
has been shown that HCMV induced the downregulation of theIFNg-mediated induction of class II MHC expression by decreasing
the level of the Jak kinase [124]. It has also been demonstrated that
HCMV interfered with the IFN-a-dependent signalling pathway in
order to escape its host’s innate immune response [125]. Indeed, in
response to IFN-a, HCMV infection leads to a decreased expression
of some components of the Jak/STAT pathway such as Jak1 and p48.
Consequently, the ISGF-3 complex is disrupted and the expression
of IFN-dependent genes such as 20,50-OAS,MxA and class I MHC are
downregulated [125].
5.3. The Gammaherpesvirinae
5.3.1. Epstein-barr virus (EBV)
EBV productively infects epithelial cells and B-lymphocytes. It
is a widespread virus known to cause infectious mononucleosis
and to be associated with Burkitt’s lymphoma. After primary
infection, it enters latency in B-lymphocytes. During the ﬁrst step
of viral infection, EBV activates both IRF7 and IRF3 [126,127].
However, this activation is rapidly inhibited upon expression of de
novo viral proteins (Fig. 11). A candidate EBV gene for the
inhibition of IRF7 activation is BZLF-1. The BZLF1 gene product, also
known as Z, Zebra, Zta or EB1, is an immediate-early protein
interacting with IRF7 to downregulate the expression of IRF7-
dependent genes such as IFN-a4, IFN-b and Tap2 [126]. In
addition, the viral tegument protein, LF2, was reported to bind the
IRF association domain (IAD) of IRF7 thus, preventing its
dimerization and the later IFN-a production [128]. The viral UL
kinase BGLF4 was also described to inhibit host innate immune
response [127]. It was demonstrated that the viral kinase BGLF4
interacted with IRF3 and provocated its phosphorylation. While
the interaction with BGLF4 did not alter neither IRF3 dimerization
nor nuclear translocation and CBP recruitment, it prevents IRF3
from binding to responsive promoters [127]. LMP2A and LMP2B
were also demonstrated to induce the IFN receptors degradation to
counteract the antiviral response [129]. The viral protein BRLF1,
also known as Rta, was reported to downregulate the transcription
of IRF3 and IRF7 [130]. Consequently, their mRNA levels, and
thereby their protein expression, are decreased resulting in an
inhibition of IFN-b expression [130].
6. Concluding remarks
The activation of the innate immune response occurs in two
waves. During the ﬁrst wave, invading pathogens are recognized
by the host’s PRRs. Those trigger the activation of several
transcription factors such as NF-kB and IRF3 which are, along
with AP-1, key regulators of IFN-b expression. During the second
wave, released IFN-b binds its cognate receptors which induce the
activation of the Jak/STAT pathway and so, leads to the activation of
the ISGs, which encode antiviral effectors such as the PKR, 20,50-
OAS, ISG15 and Mx proteins. These effectors are important for the
establishment of the antiviral response as well in the infected cells
as in the neighbouring non-infected cells preventing them from
viral invasion. Since PRRs- and type I IFNs-triggering pathways are
critical for the induction of the antiviral response, viruses have
developed numerous strategies to inhibit these pathways, so that
they can evade their host’s innate immune response and persist.
Herpesviruses are widespread throughout the world and cause
diseases in animals including humans. Furthermore, they are
known for their ability to establish a lifelong latency in their host.
Consequently, they set up numerous strategies to counteract
antiviral responses and to evade immune surveillance. In this
review,we described that de novo synthesis of viral proteins during
Herpesvirus lytic cycle renders them able to overcome their host’s
immune defences. These viral proteins often target the activation
of either IRF3 or the Jak/STAT signalling pathway. The viral proteins
P. Vandevenne et al. / Biochemical Pharmacology 80 (2010) 1955–19721970presented in this review do not constitute an exhaustive list.
Further studies would be necessary to better understand how
Herpesviruses escape the immune responses.
Finally, these viral mechanisms are important to understand
the virus–host interactionmechanisms and to develop appropriate
therapies against Herpesvirus infection.
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